DICERNA PHARMACEUTICALS INC's ticker is DRNA and the CUSIP is 253031108.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $152,861,000 | -45.5% | 7,582,396 | +0.8% | 2.30% | -45.6% |
| Q2 2021 | $280,716,000 | +47.1% | 7,521,859 | +0.8% | 4.24% | +42.2% |
| Q1 2021 | $190,836,000 | +19.4% | 7,463,291 | +2.9% | 2.98% | +11.1% |
| Q4 2020 | $159,802,000 | +22.9% | 7,253,857 | +0.4% | 2.68% | -14.3% |
| Q3 2020 | $130,021,000 | -28.4% | 7,227,413 | +1.0% | 3.13% | -38.8% |
| Q2 2020 | $181,684,000 | +42.0% | 7,152,918 | +2.7% | 5.11% | -7.2% |
| Q1 2020 | $127,913,000 | -1.2% | 6,963,135 | +18.5% | 5.51% | +12.8% |
| Q4 2019 | $129,409,000 | +45.3% | 5,874,229 | -5.3% | 4.88% | -7.8% |
| Q3 2019 | $89,067,000 | -8.1% | 6,202,425 | +0.8% | 5.30% | +2.4% |
| Q2 2019 | $96,896,000 | +6.3% | 6,152,103 | -1.1% | 5.18% | -16.8% |
| Q1 2019 | $91,167,000 | +44.4% | 6,223,036 | +5.3% | 6.22% | +5.9% |
| Q4 2018 | $63,147,000 | -24.2% | 5,907,088 | +8.2% | 5.88% | +17.8% |
| Q3 2018 | $83,337,000 | +34.9% | 5,461,124 | +8.3% | 4.99% | +12.0% |
| Q2 2018 | $61,799,000 | +28.5% | 5,044,813 | +0.3% | 4.46% | -2.6% |
| Q1 2018 | $48,082,000 | +8.9% | 5,029,462 | -0.1% | 4.58% | -37.9% |
| Q4 2017 | $44,142,000 | +269.3% | 5,035,662 | +142.2% | 7.37% | +253.9% |
| Q3 2017 | $11,954,000 | +81.4% | 2,078,991 | 0.0% | 2.08% | +49.9% |
| Q2 2017 | $6,590,000 | -6.0% | 2,078,991 | +0.8% | 1.39% | -24.8% |
| Q1 2017 | $7,014,000 | +19.2% | 2,062,991 | +1.0% | 1.85% | -16.7% |
| Q4 2016 | $5,884,000 | -50.6% | 2,043,216 | +0.8% | 2.22% | -38.5% |
| Q3 2016 | $11,918,000 | +96.0% | 2,026,894 | 0.0% | 3.60% | +73.3% |
| Q2 2016 | $6,081,000 | -44.0% | 2,026,894 | 0.0% | 2.08% | -47.3% |
| Q1 2016 | $10,864,000 | -54.5% | 2,026,894 | +0.7% | 3.94% | -50.0% |
| Q4 2015 | $23,890,000 | +45.1% | 2,012,662 | +0.4% | 7.89% | +54.3% |
| Q3 2015 | $16,463,000 | -7.8% | 2,005,238 | +56.7% | 5.12% | -1.6% |
| Q2 2015 | $17,854,000 | -25.0% | 1,279,886 | +29.2% | 5.20% | -51.7% |
| Q1 2015 | $23,813,000 | +29.6% | 990,981 | -11.2% | 10.75% | +58.1% |
| Q4 2014 | $18,380,000 | – | 1,115,981 | – | 6.80% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 1,813,392 | $67,676,000 | 17.58% |
| Bain Capital Life Sciences Investors, LLC | 3,080,237 | $114,954,000 | 7.53% |
| RTW INVESTMENTS, LP | 7,521,859 | $280,716,000 | 4.24% |
| DAFNA Capital Management LLC | 510,756 | $19,061,000 | 3.99% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 229,892 | $8,580,000 | 3.83% |
| Parkman Healthcare Partners LLC | 304,686 | $11,371,000 | 2.49% |
| Evolutionary Tree Capital Management, LLC | 141,324 | $5,274,000 | 2.43% |
| Eagle Health Investments LP | 161,125 | $6,013,000 | 2.06% |
| Lombard Odier Asset Management (Switzerland) SA | 636,011 | $23,736,000 | 1.20% |
| Woodline Partners LP | 1,000,325 | $37,332,000 | 0.70% |